Next Phase Newsletter

A family office located in the US makes approximately 2 to 3 equity investments per year into healthcare companies located in the United States. The firm does not have an average investment size as it depends on the opportunity, however – the firm looks to take a control seat when doing so as they are a value added investor. 
 
The firm is interested in services, HCIT, diagnostics, medical devices, and auxiliary services. The firm is very opportunistic within these areas and they are agnostic with regard to indication areas. The firm looks for growth stage companies located in the United States that are generating profits or close to doing so. The firm is not interested in long term deals and prefers companies with 48 months of an exit. 
 
The firm has no explicit management team requirements as the firm is a value-added investor and takes an active role in its portfolio companies. The firm requests a board seat and provides its portfolio companies with experienced talent to help improve operations. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An impact venture fund focuses on quality of life/healthcare, climate, and education, having specialized teams for each vertical. The firm is currently investing from their first fund, allocating €1M EUR for initial checks with flexibility to make follow-on investments. The firm invests in Seed rounds but can enter earlier or later. 80% of investments are made in Spain with the other 20% made across Europe. 
 
In terms of healthcare, the firm is technology agnostic and invests in solutions that help improve the quality of life for vulnerable populations: the elderly, people with chronic diseases, and people with mental or physical disabilities. For digital health companies, the firm would like to see product-market fit. 
 
The firm can act as a lead investor and join syndicates. The firm requests to take a board seat as they like to be active investors. The firm would like to see committed and diverse management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A corporate venture capital arm of a large corporation actively seeks investment opportunities. The firm develops businesses for pharmaceuticals, active pharmaceutical ingredients, and materials for pharmaceutical formulation, advanced medication. The firm is open to global opportunities. 
 
Within the life sciences, the firm is interested in digital health solutions targeting neurodegenerative diseases (ex. Amyotrophic lateral sclerosis), and immunoinflammatory diseases, (ex. Rheumatoid Arthritis and Inflammatory Bowel disease) and Diabetes. The firm is also interested in cell-based regenerative medicine startups. Typically, the firm will not consider traditional medical device or diagnostics companies. 
 
The firm is a flexible investor. The venture group has a close relationship with all other business operations within the corporation and can actively support companies by leveraging these relationships. For example, the group can help with Asia market entry and clinical trials. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A merchant bank operates investment and advisory platforms while also being an active investor on a principal basis. The firm invests in a variety of industries including media & entertainment, renewable energy, digital assets, consumer, and life sciences. The firm recently had an initial close on their inaugural life sciences fund, and is actively seeking early-stage investment opportunities in Series A to C rounds. Initial check sizes will be between $3-7M with reserved follow-on investments. The firm focuses US-based companies, and will consider those based in Europe, Israel, and other geographies who are looking to expand operations or relocate to the US. 
 
Within life sciences, the firm will consider opportunities in therapeutics, medical devices, and diagnostics. The firm does not invest in digital health or healthcare IT-based solutions. The firm is opportunistic and will consider all types of novel modalities, technologies, and disease areas that address a high unmet medical need. While the firm does invest in early-stage companies, the firm will expect companies to have a lead asset and indication in place, demonstrating strong pre-clinical data and be close to IND filing. 
 
The firm seeks to work with companies with a committed, full-time management team in place. The firm typically does not lead investment rounds and prefers to syndicate with other likeminded investors. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

As a corporate venture arm of a leading global service provider, the fund is open to investing in anywhere from seed to IPO financing rounds. Initial investment size can vary and follow-on investment is possible. The firm primarily seeks opportunities in the US, and is open to China and Europe as well. The firm does not lead rounds and prefers companies with a lead investor in place.  Depending on the investment size and deal terms, the fund may consider an observer seat or board seat. The firm makes equity investments only and does not have an equity-for-service model.  

Separately from the corporate venture arm, the parent company also runs a program for which it collaborates with over 25 partners, such as accelerators, seed/venture capital firms, incubators, and other similar programs to provide startups various tools and resources to accelerate biologics and vaccine development, including credits for the firm’s technology platforms. Startups must be an active participant or referred by a Program Partner to be eligible. 
 
The firm will consider a wide range of biotech assets, from antibody drug, protein therapeutics, vaccines, DNA and mRNA drugs. The fund is also open to orphan drugs. One type of asset that the fund does not consider cell and gene therapy. 
 
The firm does not lead rounds therefore would only invest when a lead investor is secured. The fund is open to working with new or first time founders but hopes to see that the team has a good supportive network. The fund is interested in working with founders who are open to advice and suggestions. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm based in Seattle, Washington is looking to make another 10 investments with its current fund. The fund primarily invests in Series A, but is open to Seed and Series B. The typical check size is between $250K – $2M, dependent on the stage of investment. The firm identifies themselves as very involved investors and will not invest until they see a clear path through which they can add value to the company. The firm has a strong diversity lens and looks for diverse teams including women and individuals of different backgrounds. The firm invests in USA based companies. 

 
The firm will invest in therapeutics, diagnostics, medical devices, and digital health. The fund is particularly interested in companies targeting health related issues impacting underserved populations and geographies, such as diabetes, cancer, femtech, and cardiovascular health. The fund looks for therapeutics companies to be within 6 months of submission for phase 1 trials. The fund will look at medical device companies within 6 months of 510(k) approval. The fund also requires that there is an MVP and customer attraction but does not require there to be revenue. Similarly with diagnostics, the firm requires an MVP but does not require revenue. The fund does require digital health companies to have revenue. 
 
The firm prefers to work with management teams with prior experience with startups or within the industry, but is not a firm requirement. The firm will lead or co-invest. The firm requires a board seat when leading rounds. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A firm based in Europe raised a second fund with €60M under management for Pre-Seed, Seed, and Series A investments. The fund is backed by a majority of private investors with the support of a number of institutional investors such as European Investment Fund (EIF). The firm invests €1-2M as a seed investment in the form of equity or convertible notes to help companies advance into preclinical proof of concept and can continue investing up to €6M. If additional funds are needed, the firm seeks co-investments from the strong network of investors they have in Europe. The firm is looking for investments across Europe. 
 
The firm invests in the biotech sector, exclusively in the drug development space, and with a preference for Advanced Therapies and Synthetic Biology. The firm has an interest in cutting edge technology, and it specializes in tech transfer opportunities. The firm is agnostic indication-wise and will invest in projects in preclinical stage that have reached an in vivo proof of concept in an animal model relevant for the disease for which the therapy is being developed. 
 
The firm looks for companies with a scientific founder, and preferably a C-Level executive with a track record in biotech or pharmaceutical companies. The firm prefers to lead or co-lead in Seed stage therapeutics companies and will seek a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.